Igc pharma reports third quarter fiscal 2025 results

Potomac, maryland / access newswire / february 18, 2025 / igc pharma, inc. ("igc" or the "company") (nyse american:igc) today announced its financial results for the third fiscal quarter of 2025 ended december 31, 2024. "the third quarter of fiscal 2025 was marked by our progress in advancing igc-ad1 in our phase 2 calma trial aimed at reducing agitation in alzheimer's," said mr.
IGC Ratings Summary
IGC Quant Ranking